|
|
|
|
||
|
(State of incorporation)
|
(Commission File No.)
|
(IRS Employer Identification No.)
|
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
|
|
The
|
|
Item 2.02
|
Results of Operations and Financial Condition
|
|
Item 9.01
|
Financial Statements and Exhibits
|
|
Exhibit No.
|
Description
|
|
99.1
|
|
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document)
|
|
Date: August 14, 2024
|
TALPHERA, INC.
|
|
|
|
By:
|
/s/ Raffi Asadorian
|
|
|
Raffi Asadorian
|
|
|
|
Chief Financial Officer
|
|
Exhibit 99.1
Talphera Announces Second Quarter 2024 Financial Results and Provides Corporate Update
NEPHRO CRRT study patient screening has initiated at multiple clinical sites
The safety and effectiveness of nafamostat is being assessed in the NEPHRO CRRT registrational study in 166 patients at up to 14 clinical sites
Cash and investments at June 30, 2024 of $14.0 million
Conference call and webcast to be held Wednesday, August 14, 2024 at 4:30 pm ET
SAN MATEO, Calif., August 14, 2024 – Talphera, Inc. (Nasdaq: TLPH), (“Talphera”), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced second quarter 2024 financial results and provided a corporate update.
“We’re excited to have initiated the screening of patients at multiple clinical sites in the NEPHRO CRRT registrational study. We now have finalized clinical trial agreement terms with eight large academic institutions including our potentially highest enrolling sites. We have also received FDA approval to increase the maximum number of study sites from 10 to 14 which we believe will help expedite completion of the study,” stated Vince Angotti, CEO of Talphera. “The NEPHRO study should be enrolled and completed efficiently given the measurement of the primary endpoint is at 24 hours, with patients completing the study after 72 hours. In addition, having Breakthrough Device Designation from the FDA potentially provides an advantage for a timely approval of the product candidate next year. Nafamostat has the potential to address known disadvantages of currently available U.S. products for anticoagulation of the extracorporeal circuit and has been used, as a standard of care, in Japan and South Korea for over 30 years. We’re looking forward to making nafamostat available to healthcare providers in the United States, if approved,” continued Angotti.
Dr. Shakil Aslam, Talphera’s Chief Development Officer, has been leading the NEPHRO CRRT study since joining the Company. Dr. Aslam’s expertise in nephrology and his 20 years of experience in academia and drug and device development has already proven to be an asset. Oversight of the NEPHRO study transitioned to Dr. Aslam from Dr. Palmer, Talphera’s Chief Medical Officer, who, after nearly two decades in this role, will be retiring in October. Upon Dr. Palmer’s retirement, Dr. Aslam will succeed her as Talphera’s Chief Medical Officer and Dr. Palmer will continue as a consultant to the Company until completion of the NEPHRO study.
“On behalf of the Board and the entire organization, I want to thank Pam for her leadership and dedication over her many years of service with the Company. We wish her all the best with her well-deserved retirement after co-founding Talphera and serving on the Board and as Chief Medical Officer for the last 19 years. Pam has been the scientific and medical force behind the Company, successfully achieving a U.S. drug approval and two European drug approvals. It has been a privilege to work with Dr. Palmer over the past seven years and I am grateful that Pam has agreed to remain as a consultant until the NEPHRO study has been completed. Additionally, we are delighted to have Dr. Aslam on board. Shakil is already making major contributions to Talphera, including expediting activities with the NEPHRO study,” stated Vince Angotti.
Second quarter 2024 and recent highlights
|
● |
Screening has been initiated at multiple clinical sites in the NEPHRO CRRT registrational study. The NEPHRO CRRT study will enroll 166 patients undergoing continuous renal replacement therapy (CRRT) at up to 14 clinical sites across the United States. The primary endpoint of the study is the mean post-filter activated clotting time for circuits infused with nafamostat compared against placebo over the first 24 hours. |
|
● |
Clinical trial agreement terms with eight large academic institutions have been finalized with the final four site initiation visits of these initial eight institutions scheduled to be completed this month. |
|
● |
Dr. Shakil Aslam joined Talphera effective May 20, 2024 as Chief Development Officer. Dr. Aslam has over 20 years of clinical and research experience across a broad therapeutic range including renal and vascular disease and acute kidney injury. He joined Talphera from BioCryst Pharmaceuticals where he was the Vice President, Clinical Development, Nephrology and Rare Diseases. Dr. Aslam previously held roles at Angion Biomedica, Fresenius Medical Care and Amgen and was an assistant professor at Georgetown University hospital for twelve years with a focus on acute and chronic kidney disease, hypertension, renal transplantation, and other nephrological diseases. |
Second Quarter 2024 Financial Information
|
● |
The cash, cash equivalents and investments balance was $14.0 million as of June 30, 2024. |
|
● |
Combined R&D and SG&A expenses for the second quarter of 2024 totaled $4.3 million compared to $4.2 million for the second quarter of 2023. Excluding non-cash stock-based compensation expense, these amounts were $4.0 million for the second quarter of 2024, compared to $3.8 million for the second quarter of 2023. The increase in combined R&D and SG&A expenses in the second quarter of 2024 was primarily due to an increase in costs associated with Niyad development. |
|
● |
For the second quarter of 2024, the Company recognized net loss from continuing operations of $3.8 million, as compared to net loss of $4.4 million for the second quarter of 2023, largely due to the change in fair value of the Company’s warrant liability. The divestment of DSUVIA represents a discontinued operation; accordingly, all historical operating results for the business are reflected within discontinued operations. There were no DSUVIA related expenses in the second quarter of 2024. |
|
● |
Net loss attributable to common shareholders for the second quarter of 2024 was $3.8 million, or $0.15 per basic and diluted share, compared to a net loss of $4.4 million, or $0.40 per basic and diluted share, for the second quarter of 2023. |
Conference Call and Webcast Information
Talphera will hold a conference call and webcast at 4:30 p.m. Eastern Daylight Time/1:30 p.m. Pacific Daylight Time to discuss the results and provide an update on the Company’s business.
Investors who wish to participate in the conference call may do so by dialing 1-800-836-8184 for North American callers, or 1-646-357-8785 (toll applies) for international callers outside of Canada. The conference ID is 28132. The webcast can be accessed here or by visiting the Investors section of the Company's website at www.talphera.com and clicking on the webcast link posted within Investors/News & Events/Upcoming Events section. The webcast will include a slide presentation and a replay will be available on the Talphera website for 90 days following the event.
About Talphera, Inc.
Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Talphera's lead product candidate, Niyad™ is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit, and has received Breakthrough Device Designation status from the U.S. Food and Drug Administration (FDA).
This release is intended for investors only. For additional information about Talphera, please visit www.talphera.com.
About Niyad and nafamostat
Nafamostat is a broad spectrum, synthetic serine protease inhibitor with anticoagulant, anti-inflammatory and potential anti-viral activities. Niyad™ is a lyophilized formulation of nafamostat and is currently being studied under an IDE, as an anticoagulant for the extracorporeal circuit, and has received Breakthrough Device Designation Status from the FDA. Talphera’s registrational study of Niyad™ is named the NEPHRO CRRT (Nafamostat Efficacy in Phase 3 Registrational Continuous Renal Replacement Therapy) study. An ICD-10 procedural code, XY0YX37, has been issued for the extracorporeal introduction of nafamostat. The ICD-10 code is a specific/billable code that can be used to indicate a procedure. LTX-608 is a proprietary nafamostat formulation for direct IV infusion that may be investigated and developed for the treatment of acute respiratory distress syndrome (ARDS), disseminated intravascular coagulation (DIC), acute pancreatitis or as an anti-viral treatment, amongst other potential targets.
About the NEPHRO CRRT Study
The NEPHRO Study, which has received central IRB approval, is designed as a prospective, double-blinded trial to be conducted at up to 14 U.S. hospital intensive care units. The study will enroll and evaluate 166 adult patients undergoing renal replacement therapy, who cannot tolerate heparin or are at risk for bleeding. The primary endpoint of the study is mean post-filter activated clotting time using Niyad versus placebo over the first 24 hours. Key secondary endpoints include filter lifespan, number of filter changes over 72 hours, number of transfusions over 72 hours and dialysis efficacy (based on urea concentration) over the first 24 hours.
Forward-looking statements
This press release contains forward-looking statements based upon Talphera's current expectations and assumptions. These and any other forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking terminology such as “believe,” “expect,” “finalize,” “may,” “if,” “intends,” “plans,” “potential,” ”projected,” “will,” or the negative of these words or other comparable terminology, and include: Talphera’s expectation that the NEPHRO study will enroll and complete efficiently, the potential of nafamostat to address unmet needs in anticoagulation of the extracorporeal circuit, and the potential advantage of having Breakthrough Device Designation and potential FDA approval of the nafamostat product candidate. Talphera’s discussion of its strategy, plans and intentions also include forward-looking statements, which are predictions, projections and other statements about future events that are based on current expectations and assumptions. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied by such statements, including: (i) risks relating to Talphera's product development activities, including that clinical studies may not be fully enrolled or completed and/or confirm any safety, efficacy or other potential developmental product characteristics described or assumed in this press release; (ii) Talphera’s developmental product candidates may not be beneficial to patients or healthcare providers or be successfully commercialized; (iii) risks relating to Talphera’s ability to obtain regulatory approvals for its developmental product candidates; (iv) risks related to the ability of Talphera and its business partners to implement development plans, commercial launch plans, forecasts and other business expectations; and (v) risks related to Talphera's liquidity and its ability to maintain capital resources sufficient to conduct its clinical studies. Although it is not possible to predict or identify all such risks and uncertainties, they may include, but are not limited to, those described under the caption “Risk Factors” and elsewhere in Talphera's annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. You are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date such statements were first made. To the degree financial information is included in this press release, it is in summary form only and must be considered in the context of the full details provided in Talphera's most recent annual, quarterly or current report as filed or furnished with the SEC. Talphera's SEC reports are available at www.talphera.com under the “Investors” tab. Except to the extent required by law, Talphera undertakes no obligation to publicly release the result of any revisions to these forward-looking statements to reflect new information, events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events.
Investor Contacts:
Talphera
Raffi Asadorian, CFO
650-216-3500
investors@talphera.com
LifeSci Advisors
Kevin Gardner
617-283-2856
kgardner@lifesciadvisors.com
Chris Calabrese
917-680-5608
ccalabrese@lifesciadvisors.com
###
|
Selected Financial Data |
|
(in thousands, except per share data) |
|
(unaudited) |
|
Three Months Ended |
Six Months Ended |
|||||||||||||||
|
June 30 |
June 30 |
|||||||||||||||
|
2024 |
2023 |
2024 |
2023 |
|||||||||||||
|
Statement of Operations Data |
||||||||||||||||
|
Revenue |
$ | - | $ | 253 | $ | - | $ | 253 | ||||||||
|
Operating costs and expenses: |
||||||||||||||||
|
Research and development (1) |
1,909 | 1,552 | 3,342 | 2,599 | ||||||||||||
|
Selling, general and administrative (1) |
2,361 | 2,670 | 5,165 | 6,951 | ||||||||||||
|
Total operating costs and expenses |
4,270 | 4,222 | 8,507 | 9,550 | ||||||||||||
|
Loss from operations |
(4,270 | ) | (3,969 | ) | (8,507 | ) | (9,297 | ) | ||||||||
| - | ||||||||||||||||
|
Other income: |
||||||||||||||||
|
Interest expense |
- | (15 | ) | - | (134 | ) | ||||||||||
|
Interest income and other income, net |
201 | 858 | 421 | 1,058 | ||||||||||||
|
Gain on sale of future payments |
- | - | 1,246 | - | ||||||||||||
|
Change in fair value of warrant liability |
455 | (1,299 | ) | (547 | ) | 4,012 | ||||||||||
|
Non-cash interest expense on liability related to sale of future payments |
(213 | ) | - | (394 | ) | - | ||||||||||
|
Total other income (expense) |
443 | (456 | ) | 726 | 4,936 | |||||||||||
|
Net loss before income taxes |
(3,827 | ) | (4,425 | ) | (7,781 | ) | (4,361 | ) | ||||||||
|
Provision for income taxes |
- | (3 | ) | - | (3 | ) | ||||||||||
|
Net loss from continuing operations |
(3,827 | ) | (4,428 | ) | (7,781 | ) | (4,364 | ) | ||||||||
|
Net income (loss) from discontinued operations |
- | 57 | - | (8,159 | ) | |||||||||||
|
Net loss |
$ | (3,827 | ) | $ | (4,371 | ) | (7,781 | ) | (12,523 | ) | ||||||
|
Net (loss) income per share attributable to stockholders: |
||||||||||||||||
|
Basic and diluted, continuing operations |
$ | (0.15 | ) | $ | (0.41 | ) | $ | (0.31 | ) | $ | (0.40 | ) | ||||
|
Basic and diluted, discontinued operations |
$ | - | $ | 0.01 | $ | - | $ | (0.75 | ) | |||||||
|
Basic and diluted loss per share |
$ | (0.15 | ) | $ | (0.40 | ) | $ | (0.31 | ) | $ | (1.15 | ) | ||||
|
Shares used in computing net (loss) income per share of common stock, basic and diluted |
26,202 | 10,924 | 25,462 | 10,909 | ||||||||||||
| $ | - | |||||||||||||||
|
(1) Includes the following non-cash stock-based compensation expense: |
||||||||||||||||
| 0 | ||||||||||||||||
|
Research and development |
$ | 85 | $ | 80 | $ | 192 | $ | 173 | ||||||||
|
Selling, general and administrative |
138 | 391 | 333 | 848 | ||||||||||||
|
Discontinued operations |
- | - | - | 19 | ||||||||||||
|
Total |
$ | 223 | $ | 471 | $ | 525 | $ | 1,040 | ||||||||
|
Selected Balance Sheet Data |
|
(in thousands) |
|
June 30, 2024 |
December 31, 2023(1) |
|||||||
|
(Unaudited) |
||||||||
|
Cash, cash equivalents and investments |
$ | 14,023 | $ | 9,381 | ||||
|
Total assets |
24,856 | 20,395 | ||||||
|
Total liabilities |
12,126 | 6,290 | ||||||
|
Total stockholders' equity |
12,730 | 14,105 | ||||||
|
(1) Derived from the audited financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023. |
|
Reconciliation of Non-GAAP Financial Measures |
|
(Operating Expenses less stock-based compensation expense) |
|
Three Months Ended |
Twelve Months Ended |
|||||||||||||||
|
June 30 |
June 30 |
|||||||||||||||
|
2024 |
2023 |
2024 |
2023 |
|||||||||||||
|
Operating expenses (GAAP): |
||||||||||||||||
|
Research and development |
$ | 1,909 | $ | 1,552 | $ | 3,342 | $ | 2,599 | ||||||||
|
Selling, general and administrative |
2,361 | 2,670 | 5,165 | 6,951 | ||||||||||||
|
Total operating expenses |
4,270 | 4,222 | 8,507 | 9,550 | ||||||||||||
|
Less stock-based compensation expense |
223 | 471 | 525 | 1,021 | ||||||||||||
|
Operating expenses (non-GAAP) |
$ | 4,047 | $ | 3,751 | $ | 7,982 | $ | 8,529 | ||||||||